Yibin Feng

Tianqi Song, Yugin Tan, Zicheng Zhu et al.

Multi-agent systems - systems with multiple independent AI agents working together to achieve a common goal - are becoming increasingly prevalent in daily life. Drawing inspiration from the phenomenon of human group social influence, we investigate whether a group of AI agents can create social pressure on users to agree with them, potentially changing their stance on a topic. We conducted a study in which participants discussed social issues with either a single or multiple AI agents, and where the agents either agreed or disagreed with the user's stance on the topic. We found that conversing with multiple agents (holding conversation content constant) increased the social pressure felt by participants, and caused a greater shift in opinion towards the agents' stances on each topic. Our study shows the potential advantages of multi-agent systems over single-agent platforms in causing opinion change. We discuss design implications for possible multi-agent systems that promote social good, as well as the potential for malicious actors to use these systems to manipulate public opinion.

Junwei Su, Cheng Xin, Ao Shang et al.

This paper systematically reviews recent advances in artificial intelligence (AI), with a particular focus on machine learning (ML), across the entire drug discovery pipeline. Due to the inherent complexity, escalating costs, prolonged timelines, and high failure rates of traditional drug discovery methods, there is a critical need to comprehensively understand how AI/ML can be effectively integrated throughout the full process. Currently available literature reviews often narrowly focus on specific phases or methodologies, neglecting the dependence between key stages such as target identification, hit screening, and lead optimization. To bridge this gap, our review provides a detailed and holistic analysis of AI/ML applications across these core phases, highlighting significant methodological advances and their impacts at each stage. We further illustrate the practical impact of these techniques through an in-depth case study focused on hyperuricemia, gout arthritis, and hyperuricemic nephropathy, highlighting real-world successes in molecular target identification and therapeutic candidate discovery. Additionally, we discuss significant challenges facing AI/ML in drug discovery and outline promising future research directions. Ultimately, this review serves as an essential orientation for researchers aiming to leverage AI/ML to overcome existing bottlenecks and accelerate drug discovery.